View on GitHub

This Release contains updates to the draft version of the database. Concept mappings to RxNorm, SNOMED, and OMOP are now present for all curated therapies. We additionally curate an approval for imlunestrant from the European Medicines Agency, as well as another for belzutifan from both the European Medicines Agency and Food and Drug Administration.

Database content updates

Added entries:

  • (EMA) ER+, HER2-negative, and ERBB2 activating variants and sensitivity to imlunestrant for patients with breast cancer.
  • (EMA, FDA) VHL pathogenic variants and sensitivity to belzutifan for patients with renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors.

Revised entries:

  • (FDA) TSC1/2 oncogenic variants and sensitivity to everolimus for patients with subependymal giant cell astrocytoma was previously incorrectly associated with a different cancer type. A coding for subependymal giant cell astrocytoma was introduced and these TSC1/2 relationships were updated.
  • The initial approval date for all EMA indications was updated to reflect the European Commission approval date, rather than the publication date of referenced documents.
  • All therapies now include mappings to RxNorm, SNOMED, and OMOP, with the exception of 34 which were only represented in either RxNorm or SNOMED but not both.